CIRCUMSPOROZOITE BASED MULTIPLE ANTIGEN PEPTIDES AS MALARIA VACCINE

基于环孢子的多抗原肽作为疟疾疫苗

基本信息

  • 批准号:
    6307602
  • 负责人:
  • 金额:
    $ 0.82万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-12-01 至 2000-11-30
  • 项目状态:
    已结题

项目摘要

Over the past several years, investigators in the Department of Medical and Molecular Parasitology at the New York University School of Medicine have explored the use of multiple antigen peptides (MAPs) as the basis for vaccines against malaria. The work has focused on peptides derived from the circumsporozite protein (CSP); experimental immunogens based on the CSP of human malaria parasites have been studied for immunogenicity, while rodent malaria parasite homolog systems have enabled both immunogenicity and efficacy determinations. Sequences derived from the central repeat region of the CSP have provided to B epitopes portion of the MAPs, whereas T epitopes from several portions of the CSP have been used. MAPs have been produced which exhibit excellent immunogenicity as determined by ELISA titers against the immunogens and IFA titers against whole sporozoites. Highly immunogenic MAPs have proven to be highly protective in rodent malaria systems. One Plasmodium falcip arum MAP in particular, designated (T1B)4 has proven to be highly immunogenic. When administered with alum as adjuvant, this MAP is highly immunogenic in responder mouse strains, resulting in antibody titers orders of magnitude greater than those seen in immunization regimen is the standard used for induction of protection against malaria in a variety of host parasite systems including P.falcimarum infections in humans. Based on this information, it was decided that the MAP would be used as the basis of a vaccine and would be tested in humans. A pilot lot of MAP has been synthesized by a commercial laboratory capable of production under GMP and a GMP lot is being planned for formulation with alum. The MAP has been characterized by HPLC, SDS-PAGE, gel filtration, amino acid analysis, mass spectrometry, reactivity with reference monoclonal antibody, and immunogenicity and human trials are planned for the near future.
在过去的几年里, 纽约大学学院医学与分子寄生虫学 已经探索了使用多抗原肽(MAP) 作为疟疾疫苗的基础。 工作重点是 环孢子体蛋白(CSP)衍生肽;实验性 基于人类疟疾寄生虫CSP的免疫原已经被发现 研究了免疫原性,而啮齿类疟原虫同源物 系统已经能够进行免疫原性和功效测定。 衍生自CSP的中心重复区的序列具有 提供给MAP的B表位部分,而来自MAP的T表位 已经使用了CSP的几个部分。 已制作地图 通过ELISA滴度测定其显示出优异的免疫原性 针对免疫原和针对整个子孢子的IFA滴度。 高免疫原性MAP已被证明在啮齿动物中具有高度保护性 疟疾系统。 一种恶性疟原虫MAP, 命名为(T1 B)4的抗体已被证明是高度免疫原性的。 当 与明矾作为佐剂一起施用,这种MAP在免疫原性方面是高度免疫原性的。 应答小鼠品系,导致抗体滴度为 比免疫方案中看到的更大的幅度是 用于在各种品种中诱导抗疟疾保护的标准 包括人类恶性疟原虫感染在内的宿主寄生虫系统。 根据这一信息,决定使用MAP 作为疫苗的基础,并将在人类身上进行测试。 一个试点地段 的MAP已经由商业实验室合成, 根据GMP生产,正在计划GMP批次用于配制 用明矾 用HPLC、SDS-PAGE、凝胶电泳、紫外分光光度计、紫外分光光度计等方法对MAP进行了表征 过滤,氨基酸分析,质谱,反应性 参考单克隆抗体,免疫原性和人体试验, 计划在不久的将来。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ruth S Nussenzweig其他文献

Ruth S Nussenzweig的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ruth S Nussenzweig', 18)}}的其他基金

GAMMACELL IRRADIATOR: MALARIA VACCINE
GAMMACELL 辐照器:疟疾疫苗
  • 批准号:
    6973406
  • 财政年份:
    2004
  • 资助金额:
    $ 0.82万
  • 项目类别:
GAMMACELL IRRADIATOR: HIV
GAMMACELL 辐射器:HIV
  • 批准号:
    6973405
  • 财政年份:
    2004
  • 资助金额:
    $ 0.82万
  • 项目类别:
Gammacell Irradiator with caesium 137 source
带铯 137 源的 Gammacell 辐照器
  • 批准号:
    6730867
  • 财政年份:
    2004
  • 资助金额:
    $ 0.82万
  • 项目类别:
CORE--INSECTARY
核心--昆虫室
  • 批准号:
    6099778
  • 财政年份:
    1997
  • 资助金额:
    $ 0.82万
  • 项目类别:
CIRCUMSPOROZOITE BASED MULTIPLE ANTIGEN PEPTIDES AS MALARIA VACCINE
基于环孢子的多抗原肽作为疟疾疫苗
  • 批准号:
    6279471
  • 财政年份:
    1997
  • 资助金额:
    $ 0.82万
  • 项目类别:
CORE--PEPTIDE SYNTHESIS
核心--肽合成
  • 批准号:
    6099779
  • 财政年份:
    1997
  • 资助金额:
    $ 0.82万
  • 项目类别:
CIRCUMSPOROZOITE BASED MULTIPLE ANTIGEN PEPTIDES AS MALARIA VACCINE
基于环孢子的多抗原肽作为疟疾疫苗
  • 批准号:
    6249455
  • 财政年份:
    1996
  • 资助金额:
    $ 0.82万
  • 项目类别:
ANTIMALARIA VACCINE BASED ON AN INFLUENZA VIRUS VECTOR
基于流感病毒载体的抗疟疾疫苗
  • 批准号:
    2072859
  • 财政年份:
    1994
  • 资助金额:
    $ 0.82万
  • 项目类别:
ANTIMALARIA VACCINE BASED ON AN INFLUENZA VIRUS VECTOR
基于流感病毒载体的抗疟疾疫苗
  • 批准号:
    2072861
  • 财政年份:
    1994
  • 资助金额:
    $ 0.82万
  • 项目类别:
DESIGN AND IMMUNE MECHANISMS OF P FALCIPARUM CS VACCINE
恶性疟原虫CS疫苗的设计和免疫机制
  • 批准号:
    2074321
  • 财政年份:
    1994
  • 资助金额:
    $ 0.82万
  • 项目类别:

相似海外基金

Developing an infection-blocking pan-coronavirus vaccine
开发阻断感染的泛冠状病毒疫苗
  • 批准号:
    MR/Y019466/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Research Grant
Development of Teat-Dipping Nanoemulsion Loaded with Curcumin for Prevention of Intramammary Infection and Treatment of Mastitis as an Immune Stimulant
开发含有姜黄素的乳头浸渍纳米乳作为免疫兴奋剂预防乳房内感染和治疗乳腺炎
  • 批准号:
    24K09263
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of bactericidal bone substitutes to prevent surgical site infection
开发杀菌骨替代物以预防手术部位感染
  • 批准号:
    24K19916
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Omics approaches to decipher infection clearance and resolution in eukaryotic human pathogens
破译真核人类病原体感染清除和解决的组学方法
  • 批准号:
    502579
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
Integrating subcellular multi-omics to identify druggable metabolic markers of latent HIV infection in CD4 T-cells
整合亚细胞多组学来识别 CD4 T 细胞中潜在 HIV 感染的可药物代谢标志物
  • 批准号:
    MR/Y013093/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Research Grant
Uncovering the unconventional and multifaceted roles of histamine in bacterial infection
揭示组胺在细菌感染中的非常规和多方面的作用
  • 批准号:
    502559
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
Presymptom: development of a novel machine-learning-derived diagnostic test to rule out infection to enable enhanced clinical care and better targeted anti-microbial use
症状前:开发一种新型的机器学习诊断测试来排除感染,从而加强临床护理和更有针对性的抗菌药物使用
  • 批准号:
    10089281
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Investment Accelerator
Cannabinoids, Inflammation/Infection and Microglia: Relation to Brain and Behaviour
大麻素、炎症/感染和小胶质细胞:与大脑和行为的关系
  • 批准号:
    502602
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
Controlled Human Infection Models for advancing pertussis research and novel vaccine development
用于推进百日咳研究和新型疫苗开发的受控人类感染模型
  • 批准号:
    502603
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
Use of Opsonophagocytic Assay for Serological Evaluation of SimCell vaccines against Pseudomonas aeruginosa infection
使用调理吞噬试验对针对铜绿假单胞菌感染的 SimCell 疫苗进行血清学评估
  • 批准号:
    10108204
  • 财政年份:
    2024
  • 资助金额:
    $ 0.82万
  • 项目类别:
    Collaborative R&D
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了